• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited Ordinary Shares (NY:TEVA)

41.10 +1.85 (+4.71%)
Official Closing Price Updated: 6:30 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,821,194
Open 40.22
Bid (Size) 41.18 (1,300)
Ask (Size) 41.45 (500)
Prev. Close 39.25
Today's Range 40.12 - 42.02
52wk Range 18.82 - 40.79
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA ↗
Today 12:02 EDT
Teva Pharmaceutical Industries (NYSE:TEVA) said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for... 
Via MarketBeat
News headline image
Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia
Today 7:00 EDT
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Performance

52-Week Range
41.10
18.8252W Low 40.7952W High
1 Week
38.251W Low 40.031W High

Teva Pharmaceutical Industries Limited Ordinary Shares (TEVA) traded between $18.82 and $40.79 over the past 52 weeks and last traded at $41.10. Over the past week it ranged between $38.25 and $40.03.

Past 12 Months
+4.0%
+11.8%
+24.2%
+32.8%
+32.8%
+103.4%
1W +$1.57
1M +$4.34
3M +$8.00
6M +$10.14
YTD +$10.15
1Y +$20.89

TEVA was +103.4% over the past year, +32.8% over six months, +32.8% year to date, +4.0% in the last week.

12 Months vs Market
TEVA
+103.4%
DIA
+10.7%
SPY
+15.7%
QQQ
+22.9%
IWM
+13.1%

Over the past 12 months TEVA returned +103.4% versus DIA (Dow) +10.7%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 2.80× 3-mo avg
Today 14,821,194 3-mo avg 5.3M
1W
4.8M
1M
5.1M
3M
5.3M
6M
5.7M
YTD
6.8M
1Y
7.7M

TEVA most recently traded 14,821,194 shares against a 3-month average daily volume of 5.3M.

More News

Read More
News headline image
Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome
October 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Journal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients
October 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
Teva Pharmaceutical (NYSE:TEVA) Nears Breakout With Perfect Technical Rating and Bull Flag Setup ↗
October 01, 2026
Via Chartmill
News headline image
TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
September 30, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ↗
September 29, 2026
Via The Motley Fool
News headline image
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
September 28, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Releases Q3 2026 Aide Memoire
September 23, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
September 23, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings ↗
September 23, 2026
Via MarketBeat
Topics Bankruptcy
News headline image
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline ↗
September 22, 2026
Via MarketBeat
News headline image
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
September 18, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
September 16, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform ↗
September 14, 2026
Via MarketBeat
Topics World Trade
News headline image
Teva Pharmaceuticals Sees Pivot to Growth Accelerating on Branded Drugs, Biosimilars ↗
September 14, 2026
Via MarketBeat
News headline image
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
September 14, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
September 10, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva Announces Launch of Offering of Senior Notes
September 07, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
September 04, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study ↗
September 02, 2026
Via MarketBeat
News headline image
Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
September 02, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
September 01, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited Ordinary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited Ordinary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited Ordinary Shares trade on?
Teva Pharmaceutical Industries Limited Ordinary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited Ordinary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited Ordinary Shares?
The current price of Teva Pharmaceutical Industries Limited Ordinary Shares is 41.10
When was Teva Pharmaceutical Industries Limited Ordinary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited Ordinary Shares was at 10/09/26 06:30 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited Ordinary Shares is 45.64B
How many shares of Teva Pharmaceutical Industries Limited Ordinary Shares are outstanding?
Teva Pharmaceutical Industries Limited Ordinary Shares has 46B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap